Literature DB >> 18647620

Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy.

J Vargas1, M E Klotman, A Cara.   

Abstract

Lentiviral vectors have been shown to be good candidates for gene transfer protocols; however, prevention of insertional mutagenesis remains problematic. Here we report on the design of a conditionally replicating integrase (IN)-defective lentiviral-hybrid episomal vector in which the insertion of the SV40 promoter/origin of replication provides long-term persistence of the extrachromosomal DNA in the presence of the corresponding trans-acting T antigen (Tag) for targeted suicide gene therapy. SV40-driven GFP expression from the IN-defective lentiviral-hybrid vector was sustained only in the Tag positive 293T cell line, while expression was transient in the parental Tag deficient cell line 293. Quantitative PCR for the 2-LTR circular forms indicated that the unintegrated forms remained stable in 293T for up to 56 days post-transduction, while they were undetectable in the cell line 293 after day 14. Transduction of 293T cells with the IN-defective lentiviral-hybrid episomal vector containing the thymidine kinase (TK) gene rendered the Tag expressing cells highly susceptible to ganciclovir (GCV) treatment, as opposed to the cells infected with the control vector or in Tag negative cells. These data suggest that conditionally replicating IN-defective lentiviral-hybrid episomal vectors could prove useful as vehicles for suicide gene therapy, in particular in cells transformed by SV40.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647620     DOI: 10.1016/j.antiviral.2008.06.015

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

Review 1.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

2.  Measurement of human immunodeficiency virus type 1 preintegration transcription by using Rev-dependent Rev-CEM cells reveals a sizable transcribing DNA population comparable to that from proviral templates.

Authors:  Subashini R Iyer; Dongyang Yu; Angélique Biancotto; Leonid B Margolis; Yuntao Wu
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

3.  Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs.

Authors:  Z Wang; Z Tang; Y Zheng; D Yu; M Spear; S R Iyer; B Bishop; Y Wu
Journal:  Gene Ther       Date:  2010-04-22       Impact factor: 5.250

4.  Antiproliferative effect of double suicide gene delivery mediated by polyamidoamine dendrimers in human Tenon's capsule fibroblasts.

Authors:  Jin Yang; Liu Kun Shi; Hui Min Sun; Yan Ming Wang
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

5.  Improving the Transduction of Bone Marrow-Derived Cells with an Integrase-Defective Lentiviral Vector.

Authors:  S Louise Pay; Xiaoping Qi; Jeffrey F Willard; Juliana Godoy; Kavya Sankhavaram; Ranier Horton; Sayak K Mitter; Judith L Quigley; Lung-Ji Chang; Maria B Grant; Michael E Boulton
Journal:  Hum Gene Ther Methods       Date:  2017-12-18       Impact factor: 2.396

Review 6.  Design and Potential of Non-Integrating Lentiviral Vectors.

Authors:  Aaron Shaw; Kenneth Cornetta
Journal:  Biomedicines       Date:  2014-01-27

7.  Integrase deficient lentiviral vector: prospects for safe clinical applications.

Authors:  Chee-Hong Takahiro Yew; Narmatha Gurumoorthy; Fazlina Nordin; Gee Jun Tye; Wan Safwani Wan Kamarul Zaman; Jun Jie Tan; Min Hwei Ng
Journal:  PeerJ       Date:  2022-08-12       Impact factor: 3.061

8.  S/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection.

Authors:  Santhosh Chakkaramakkil Verghese; Natalya A Goloviznina; Amy M Skinner; Hans J Lipps; Peter Kurre
Journal:  Nucleic Acids Res       Date:  2014-01-27       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.